Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jacob H. Grauslund"'
Autor:
Mathieu Gigoux, Morten O. Holmström, Roberta Zappasodi, Joseph J. Park, Stephane Pourpe, Cansu Cimen Bozkus, Levi M. B. Mangarin, David Redmond, Svena Verma, Sara Schad, Mariam M. George, Divya Venkatesh, Arnab Ghosh, David Hoyos, Zaki Molvi, Baransel Kamaz, Anna E. Marneth, William Duke, Matthew J. Leventhal, Max Jan, Vincent T. Ho, Gabriela S. Hobbs, Trine Alma Knudsen, Vibe Skov, Lasse Kjær, Thomas Stauffer Larsen, Dennis Lund Hansen, R. Coleman Lindsley, Hans Hasselbalch, Jacob H. Grauslund, Thomas L. Lisle, Özcan Met, Patrick Wilkinson, Benjamin Greenbaum, Manuel A. Sepulveda, Timothy Chan, Raajit Rampal, Mads H. Andersen, Omar Abdel-Wahab, Nina Bhardwaj, Jedd D. Wolchok, Ann Mullally, Taha Merghoub
Publikováno v:
Science Translational Medicine. 14
The majority of JAK2V617F-negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin (CALR), resulting in a common carboxyl-terminal mutant fragment (CALRMUT), representing an attractive source of neoant
Autor:
Matthew J. Maurer, Jacob H. Grauslund, Tove Wästerlid, Tarec Christoffer El-Galaly, Pär Josefsson, Lasse Hjort Jakobsen, Judit Jørgensen, Gita Thanarajasingam, Chan Yoon Cheah, Jon Bjørn, Harald Holte, Katherine Colvin, Jacob Haaber Christensen, Thomas M. Habermann, Yngvild Nuvin Blaker, Karin E. Smedby, Katie Y. Zhu, Ingemar Lagerlöf, Daniel Molin, Fredrik Ellin, Alina S. Gerrie, Andreas Kiesbye Øvlisen, Kevin W. Song, Knut B. Smeland
Publikováno v:
Jakobsen, L H, Ellin, F, Smeland, K B, Wästerlid, T, Christensen, J H, Jørgensen, J M, Josefsson, P L, Øvlisen, A K, Holte, H, Blaker, Y N, Grauslund, J H, Bjørn, J, Molin, D, Lagerlöf, I, Smedby, K E, Colvin, K, Thanarajasingam, G, Maurer, M J, Habermann, T M, Song, K W, Zhu, K Y, Gerrie, A S, Cheah, C Y & El-Galaly, T C 2020, ' Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients ', British Journal of Haematology. Supplement, vol. 189, no. 4, pp. 661-671 . https://doi.org/10.1111/bjh.16425
Jakobsen, L H, Ellin, F, Smeland, K B, Wästerlid, T, Christensen, J H, Jørgensen, J M, Josefsson, P L, Øvlisen, A K, Holte, H, Blaker, Y N, Grauslund, J H, Bjørn, J, Molin, D, Lagerlöf, I, Smedby, K E, Colvin, K, Thanarajasingam, G, Maurer, M J, Habermann, T M, Song, K W, Zhu, K Y, Gerrie, A S, Cheah, C Y & El-Galaly, T C 2020, ' Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients ', British Journal of Haematology, vol. 189, no. 4, pp. 661-671 . https://doi.org/10.1111/bjh.16425
Jakobsen, L H, Ellin, F, Smeland, K B, Wästerlid, T, Christensen, J H, Jørgensen, J M, Josefsson, P L, Øvlisen, A K, Holte, H, Blaker, Y N, Grauslund, J H, Bjørn, J, Molin, D, Lagerlöf, I, Smedby, K E, Colvin, K, Thanarajasingam, G, Maurer, M J, Habermann, T M, Song, K W, Zhu, K Y, Gerrie, A S, Cheah, C Y & El-Galaly, T C 2020, ' Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients ', British Journal of Haematology, vol. 189, no. 4, pp. 661-671 . https://doi.org/10.1111/bjh.16425
Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b06ef4714ed7f89c9d7439d43f1e4f
https://pure.au.dk/portal/da/publications/minimal-relapse-risk-and-early-normalization-of-survival-for-patients-with-burkitt-lymphoma-treated-with-intensive-immunochemotherapy(2ebd13a6-7c33-40b7-8ca2-3a2c0b6eebee).html
https://pure.au.dk/portal/da/publications/minimal-relapse-risk-and-early-normalization-of-survival-for-patients-with-burkitt-lymphoma-treated-with-intensive-immunochemotherapy(2ebd13a6-7c33-40b7-8ca2-3a2c0b6eebee).html
Autor:
Karin E. Smedby, Katie Yuan Zhu, Alina S. Gerrie, Knut B. Smeland, Pär Josefsson, Katherine Colvin, Lasse Hjort Jakobsen, Chan Yoon Cheah, Kevin W. Song, Jon Bjoern, T.C. El-Galaly, Ingemar Lagerlöf, Fredrik Ellin, Harald Holte, Daniel Molin, Tove Wästerlid, Matthew J. Maurer, Yngvild Nuvin Blaker, Jacob Haaber Christensen, Jacob H. Grauslund, Gita Thanarajasingam, Thomas M. Habermann, Judit Jørgensen
Publikováno v:
Ellin, F, Smeland, K B, Wästerlid, T, Christensen, J H, Jørgensen, J, Josefsson, P L, Holte, H, Blaker, Y N, Grauslund, J H, Bjørn, J, Molin, D G, Lagerlöf, I, Smedby, K E E, Colvin, K, Thanarajasingam, G, Maurer, M J, Habermann, T M, Song, K, Zhu, K Y, Gerrie, A S, Cheah, C Y, El-Galaly, T C & Jakobsen, L H 2019, ' Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy : An International Study of 108 Patients ', Blood, vol. 134, no. Suppl. 1, 4113 . https://doi.org/10.1182/blood-2019-127995
Introduction: Non-endemic Burkitt lymphoma (BL) is a rare and highly aggressive B-cell malignancy, of whom a substantial number are adolescents and young adults (AYAs). In this particular group of patients, the balance between efficacy and long-term
Autor:
Pär Josefsson, Fredrik Ellin, Yngvild Nuvin Blaker, Alina S. Gerrie, Harald Holte, Lasse Hjort Jakobsen, Knut B. Smeland, Karin Ekstroem Smedby, Judit Jørgensen, Katherine Colvin, Jon Bjørn, Ingemar Lagerlöf, Tove Wästerlid, Daniel Molin, Chan Yoon Cheah, Jacob Haaber Christensen, Jacob H. Grauslund, Tarec Christoffer El-Galaly, Gita Thanarajasingam
Publikováno v:
Jakobsen, L H, Ellin, F, Smeland, K B, Wästerlid, T, Christensen, J H, Jørgensen, J, Josefsson, P L, Holte, Jr., H, Blaker, Y N, Grauslund, J H, Bjørn, J, Molin, D, Lagerlöf, I, Smedby, K E, Colvin, K, Thanarajasingam, G, Gerrie, A S, Cheah, C Y & El-Galaly, T C 2018, ' Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy : An International Study of 159 Real-World Patients ', Blood, vol. 132, no. Suppl. 1, pp. 452 . https://doi.org/10.1182/blood-2018-99-111748
Jakobsen, L H, Ellin, F, Smeland, K B, Wasterlid, T, Christensen, J H, Jorgensen, J, Josefsson, P L, Holte, Jr., H, Blaker, Y N, Grauslund, J H, Bjorn, J, Molin, D, Lagerlof, I, Smedby, K E, Colvin, K, Thanarajasingam, G, Gerrie, A S, Cheah, C Y & El-Galaly, T C 2018, ' Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients ', Blood, vol. 132, no. Suppl. 1 . https://doi.org/10.1182/blood-2018-99-111748
Jakobsen, L H, Ellin, F, Smeland, K B, Wasterlid, T, Christensen, J H, Jorgensen, J, Josefsson, P L, Holte, Jr., H, Blaker, Y N, Grauslund, J H, Bjorn, J, Molin, D, Lagerlof, I, Smedby, K E, Colvin, K, Thanarajasingam, G, Gerrie, A S, Cheah, C Y & El-Galaly, T C 2018, ' Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients ', Blood, vol. 132, no. Suppl. 1 . https://doi.org/10.1182/blood-2018-99-111748
Background: Non-endemic Burkitt lymphoma (BL) is a rare B-cell malignancy characterized by extreme tumor proliferation, frequent extranodal involvement, and the genetic hallmark of a MYC gene rearrangement. Despite an often dramatic initial presentat